Download PDF
Pharmacopsychiatry 2008; 41(4): 165-166
DOI: 10.1055/s-2008-1076725
Letter

© Georg Thieme Verlag KG Stuttgart · New York

Anxiety, Phobia and Nadolol Abuse: A Case Report

C. Victorri-Vigneau 1 , M. Bronnec 2 , S. Prétagut 2 , P. Jolliet 1
  • 1Center for Evaluation and Information on Pharmacodependence, Clinical Pharmacology Department, Nantes University Hospital, Nantes, France
  • 2Psychiatry Department, Nantes University Hospital, Nantes, France
Further Information

Publication History

received 09.07.2007 revised 16.01.2008

accepted 28.01.2008

Publication Date:
23 July 2008 (online)

Also available at
    Permissions and Reprints

In France, one of the main missions of CEIP (Centres for the assessment and Information on Pharmacodependence) is to collect data and assess the potential of dependence on psychoactive drugs (under French regulations it is mandatory for health professionals to notify the relevant territorial CEIP in case of drug abuse or pharmacodependence): we present the case of a 24-year-old man who developed dependence on nadolol. Dependence adverse effects are not listed actually in the beta-blocker drugs monograph. Clearly, it seems that their use can lead to abuse. Therefore it is essential to communicate with health professionals about this phenomena; particularly the increase of posologies must be supervised with great care. Thus, it is useful and important to draw the attention of doctors to the possible abuse and misuse of beta-blocker, which has not been published and is not listed actually in the drug monograph.

References

  • 1 Aarons R, Nies A, Gal J, Hegstrand L, Molinoff P. Elevation of β-adrenergic receptor density in human lymphocytes after propranolol administration.  J Clin Invest. 1980;  65 949-957
    CrossrefPubMedGoogle Scholar
  • 2 Barcellos Fontanella BJ. Social anxiety and propranolol abuse: a case study.  Rev Bras Psiquiatr. 2003;  25 228-230
    PubMedGoogle Scholar
  • 3 Bawert A, Fischer G. Addiction – who is not affected?.  Wien Med Wochenschr. 2005;  155 549-561
    CrossrefPubMedGoogle Scholar
  • 4 DSM-IV .Manuel diagnostique et statistique des troubles mentaux. 4èmeédition. Trad. Paris, Masson 1996
  • 5 Jolliet-Riant P, Tillement JP. Drug transfer across the blood-brain barrier and improvement of brain delivery.  Fundam Clin Pharmacol. 1999;  13 16-26
    PubMedGoogle Scholar
  • 6 Stemmelin J, Cohen C, Terranova JP. et al . Stimulation of the beta(3)-adrenoreceptor as a novel treatment strategy for anxiety and depressive disorders.  Neuropsychopharmacology. 2008;  33(3) 574-587
    CrossrefPubMedGoogle Scholar
  • 7 Victorri-Vigneau C, Guerlais M, Jolliet P. Abuse, dependence and withdrawal with gabapentin : first case report.  Pharmacopsychiatry. 2007;  40 43-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 http://www.dopage.com consulted on June 30, 2006

Correspondence

C. Victorri-Vigneau

Centre d'Evaluation et d'Information sur la Pharmacodependance

Service de Pharmacologie Clinique

9 quai Moncousu

44093 Nantes cedex 1

France

Phone: +33/2/4008 40 96

Email: Caroline.vigneau@chu-nantes.fr

      >